

Maintenance treatment for metastatic adenocarcinoma in the elderly (age 80)

An 80-year-old patient with asymptomatic, low tumor burden, pan-wild-type metastatic NSCLC

Most Common Maintenance Therapy Choices Based on Induction Regimen

Induction regimen	Most common maintenance therapy
Carboplatin/pemetrexed	Pemetrexed (89%)
Carboplatin/pemetrexed/bevacizumab	Pemetrexed/bevacizumab (52%)
Carboplatin/paclitaxel/bevacizumab	Bevacizumab (58%)

EDITOR'S COMMENTS

Nearly all survey respondents who would employ carboplatin/pemetrexed as induction therapy for an 80-year-old patient would go on to offer pemetrexed maintenance. Both faculty members endorse this strategy, and although Dr Ramalingam finds pemetrexed to be well tolerated in elderly patients, he individualizes the decision about maintenance and for how long to use it based on many factors, including the extent of the disease and related symptomatology, the severity of toxicities and the patient's goals and expectations.

SELECT REFERENCES WITH LINKS

Cappuzzo F et al. **Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study.** *Lancet Oncol* 2010;11(6):521-9. [Abstract](#)

Gerber DE et al. **Maintenance chemotherapy for advanced non-small-cell lung cancer: New life for an old idea.** *J Clin Oncol* 2013;31(8):1009-20. [Abstract](#)

Owonikoko TK et al. **Maintenance therapy for advanced non-small cell lung cancer: Current status, controversies, and emerging consensus.** *Clin Cancer Res* 2010;16(9):2496-504. [Abstract](#)

Paz-Ares LG et al. **PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.** *J Clin Oncol* 2013;31(23):2895-902. [Abstract](#)